\n
\nLondon, Oct 26 (PTI) COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.<\/p>\n
\n
There have been reports of rare neurological complications associated with SARS-CoV-2 infection and Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccines.<\/p>\n
The study, published in the journal Nature Medicine on Monday, analysed anonymised healthcare records of over 32 million people across England.<\/p>\n
The researchers assessed the risk of developing neurological complications within 28 days of a first dose of either the AstraZeneca vaccine, known as Covishield in India, or Pfizer preventive, or within 28 days of testing positive for COVID-19.<\/p>\n
They found an increased, but low, risk of the rare neurological conditions Guillain-Barre syndrome and Bell’s palsy following a first dose of the AstraZeneca vaccine and an increased but low risk of hemorrhagic stroke following a first dose of the Pfizer vaccine.<\/p>\n
However, infection with COVID-19 was associated with a greater risk of developing neurological complications than receiving either vaccine, according to the researchers.<\/p>\n
“This analysis provides important information about which neurological conditions could be linked with COVID-19 vaccination or infection,” said Professor Carol Coupland from the University of Nottingham, UK, one of the researchers involved in the study.<\/p>\n
“Overall, the findings from this study show that the risks of hospital admission with nervous system complications associated with COVID-19 infection are greater than the risks associated with COVID-19 vaccinations,” Coupland said.<\/p>\n
The researchers found different risks for different types of neurological conditions depending on which vaccine people received.<\/p>\n
However, these were substantially lower than the risks occurring in association with a positive COVID-19 PCR test.<\/p>\n
“For example, we estimate 145 excess cases of Guillain-Barre syndrome per 10 million people in the 28 days after a positive SARS-CoV-2 test, compared to 38 per 10 million for those who received the AstraZeneca vaccine,” said Martina Patone from the University of Oxford, and co-lead author of the study.<\/p>\n
The researchers noted that the initial clinical trials of the vaccines were not large enough to be able to detect very rare adverse neurological events — those that happen in less than 1 person out of 10,000.<\/p>\n
The latest study was able to achieve this by looking at the real-world data from over 32 million healthcare records in England, they said.<\/p>\n
The study used what is known as a “self-controlled case series (SCCS)” design.<\/p>\n
An SCSS compares how often adverse events — in this case neurological complications happen in different set windows of time.<\/p>\n
The authors noted several limitations to the study, including that only risks associated with the first vaccine dose were examined.<\/p>\n
Data on outcomes following second doses was limited at the time of this study since the vaccination programme in the UK is still underway.<\/p>\n
The researchers could also not distinguish between different types of Guillain-Barre syndrome due to the way healthcare records were coded.<\/p>\n
\n","protected":false},"excerpt":{"rendered":"
London, Oct 26 (PTI) COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK. There have been reports of rare neurological complications associated with SARS-CoV-2 infection and Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccines. The study, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":{"0":"post-175182","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-world"},"_links":{"self":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts\/175182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/comments?post=175182"}],"version-history":[{"count":0,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts\/175182\/revisions"}],"wp:attachment":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/media?parent=175182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/categories?post=175182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/tags?post=175182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}